Virtual Library
Start Your Search
T. Herrmann
Author of
-
+
P2.08 - Poster Session with Presenters Present (ID 491)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Patient Support and Advocacy Groups
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.08-002 - Online Patient Education in Advanced Lung Cancer: Effect on Patient/Caregiver Knowledge (ID 5488)
14:30 - 14:30 | Author(s): T. Herrmann
- Abstract
Background:
Recent studies have found that patients with lung cancer consistently report suboptimal communication with their physicians which, in turn, can limit shared decision making and impair clinical outcomes. To address this gap, a patient/caregiver-focused educational initiative was developed to determine if online education modules could improve knowledge about treatment decisions and side effect management in advanced non-small cell lung cancer (NSCLC).
Methods:
The initiative consisted of 4 educational activities available on WebMD Education, a website dedicated to patient/caregiver learning. Each activity included demographic questions and a pre-/post-activity question to measure impact on knowledge. The activities launched online in between August and October, 2015, and data were collected through April, 2016.
Results:
After 9 months, a total of 8933 persons had participated in the education. Of those, 43% had lung cancer or were caregivers of a person with the disease, and 65% were female. The average age of individuals who participated in any 1 of the 4 activities varied based on topic. Significant post-participation improvements in knowledge were observed including: ·8% increase in comprehending that treatment-related side effects should be reported to their cancer care team both while on therapy and after completion of treatment with a cancer immunotherapy ·16% increase in understanding the mechanism of action associated with use of cancer immunotherapies in the treatment of lung cancer (p < 0.001) ·26% increase in recognizing first response with cancer immunotherapies will take longer than chemotherapy (p < 0.001) ·28% increase in understanding that molecular testing is necessary in individuals with advanced NSCLC, adenocarcinoma, in order to select the most appropriate treatment
Conclusion:
This study demonstrates that well-designed online patient/caregiver-focused education can be successful in improving familiarity with essential elements involved in the management of advanced lung cancer. Targeted and focused digital education empowers, engages and equips patient/caregiver with information needed for self-care condition management.
-
+
P3.02b - Poster Session with Presenters Present (ID 494)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-049 - EGFR-Mutated NSCLC: Clinical Practice Assessment and Gap Analysis (ID 4707)
14:30 - 14:30 | Author(s): T. Herrmann
- Abstract
Background:
For patients with advanced NSCLC, mutations in the epidermal growth factor receptor (EGFR) gene predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Consequently, EGFR TKIs in both the first and second line (for T790M +ve) are now considered the standard of care. This study’s objective was to assess current clinical practices of oncologists and pathologists in the management of EGFR-mutated NSCLC to identify knowledge, competency, and practice gaps and barriers to improving patient care.
Methods:
An educational needs assessment consisting of 25 questions was developed. The assessment design included case vignettes and knowledge- and case -based, questions based on evidence-based consensus guidelines. The assessment was made available online to healthcare providers without monetary compensation or charge. Confidentiality of survey respondents was maintained and responses were de-identified and aggregated prior to analyses. The assessment launched on February 26, 2016, and responses were collected through June 10, 2016.
Results:
In total, 226 US physicians responded to the survey. Respondents were most likely to be oncologists. Practice setting was almost evenly divided between academic and community. . Knowledge gaps: 40% of oncologists and 52% of pathologists were unable to correctly identify the IASLC guideline recommendations on molecular profiling while 45% of oncologists and 54% of pathologists could not identify the efficacy of approved first line EGFR TKIs. Confidence gaps: Less than 10% of oncologists and pathologists are very confident in their understanding of liquid biopsies. In addition, only 23% of oncologists were very confident in their ability to individualize first line treatment. Performance gaps: Between 43%-60% of oncologists and pathologists incorrectly indicted they would prescribe first line therapy for a patient with an activating EGFR mutation. Despite an available therapy for patients with an identified T790M mutation, 41%-72% oncologists and pathologists indicated they would not undertake a biopsy in a patient with EGFR-mutated NSCLC that had progressed on a first line EGFR TKI and only 12% of oncologists noted that they always test to determine the mechanism of resistance. One-third of oncologists indicated would not select the most appropriate treatment option for a patient whose disease progressed on first line EGFR TKI therapy and whose tumor did not contain a T790M mutation.
Conclusion:
This assessment of clinical practices provided insights into gaps in the knowledge, competency and practices regarding molecular testing and management of EGFR-mutated NSCLC. Focused educational efforts are urgently needed to inform the practicing physicians on recent advances in targeted therapy for advanced NSCLC.
